睿知中国医院研究地图
候选清单

北京

首都医科大学附属北京胸科医院

Beijing Chest Hospital

在本站收录的 61 种疾病中,这家医院列在其中 3 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

首都医科大学附属北京胸科医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 肺癌Lung cancer80 篇牵头论文牵头 2 项开放试验
  2. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  3. 特发性肺纤维化Idiopathic pulmonary fibrosis0 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝细胞癌、胃癌、胰腺癌、乳腺癌、胶质瘤、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、骨肉瘤、胃肠道间质瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、淋巴瘤、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、冠心病、先天性心脏病、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 80 篇,占 0.3%。

牵头论文
80
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
27
由其他机构牵头
每年牵头的论文数
2021: 121220212022: 151520222023: 171720232024: 141420242025: 20202025

北京有 20 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 29

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
    分期
    II期
    开始
    2024-05
    发布
    登记号
    NCT06421298

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:首都医科大学附属北京胸科医院北京

  2. 正在招募
    Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
    分期
    II期
    开始
    2024-08
    发布
    登记号
    NCT06467617

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:首都医科大学附属北京胸科医院北京

  3. 正在招募
    Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
    分期
    III期
    开始
    2026-01
    发布
    登记号
    NCT07195695

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 26 家列出的医院为研究中心上海、临沂、北京、南京、南昌、台州、哈尔滨、天津、广州、徐州、成都、扬州、杭州、武汉、济南、石家庄、苏州、郑州、长春、长沙

  4. 正在招募
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    分期
    III期
    开始
    2026-01
    发布
    登记号
    NCT07222566

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、台州、合肥、太原、广州、成都、扬州、新乡、杭州、武汉、江门、洛阳、济南、温州、福州、襄阳、郑州、重庆、长春、长沙

  5. 正在招募
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
    分期
    III期
    开始
    2026-04
    发布
    登记号
    NCT07472517

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、哈尔滨、天津、太原、宁波、广州、徐州、成都、扬州、杭州、武汉、济南、温州、福州、蚌埠、襄阳、郑州、长沙

  6. 正在招募
    A Study of DS-3939a in Participants With Solid Tumors
    分期
    I/II期
    开始
    2026-10
    发布
    登记号
    NCT07739966

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、台州、哈尔滨、天津、广州、杭州、武汉、济南、郑州、长春、长沙

  7. 正在招募
    Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
    分期
    II/III期
    开始
    2025-01
    发布
    登记号
    NCT06712316

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、北京、台州、扬州、杭州、武汉、汕头、济南、石家庄、苏州、蚌埠、重庆、长春、长沙

  8. 正在招募
    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
    分期
    III期
    开始
    2025-02
    发布
    登记号
    NCT06712355

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、临沂、北京、南昌、台州、合肥、哈尔滨、太原、广州、扬州、新乡、杭州、武汉、汕头、济南、温州、石家庄、福州、苏州、蚌埠、襄阳、郑州、重庆、长春

  9. 正在招募
    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
    分期
    III期
    开始
    2025-07
    发布
    登记号
    NCT06758401

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、台州、合肥、哈尔滨、天津、常州、广州、徐州、成都、杭州、武汉、洛阳、济南、温州、福州、西安、郑州、长沙

  10. 正在招募
    Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
    分期
    未注明
    开始
    2025-02
    发布
    登记号
    NCT06809764

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 30 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、厦门、合肥、广州、杭州、武汉、沈阳、济南、深圳、石家庄、福州、郑州、青岛

  11. 正在招募
    A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
    分期
    II期
    开始
    2025-09
    发布
    登记号
    NCT06855771

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心临沂、北京、南宁、南昌、厦门、台州、杭州、济南

  12. 正在招募
    A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
    分期
    III期
    开始
    2025-04
    发布
    登记号
    NCT06875310

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、广州、成都、扬州、新乡、杭州、武汉、汕头、沈阳、济南、深圳、石家庄、福州、苏州、蚌埠、重庆、长春、长沙

  13. 正在招募
    A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
    分期
    II期
    开始
    2025-06
    发布
    登记号
    NCT06962865

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心临沂、北京、哈尔滨、天津、太原、广州、成都、昆明、杭州、桂林、武汉、济南、温州、烟台、石家庄、福州、襄阳、郑州、重庆、长春、长沙

  14. 正在招募
    A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
    分期
    III期
    开始
    2025-06
    发布
    登记号
    NCT07010263

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、哈尔滨、天津、太原、安阳、广州、新乡、武汉、江门、沈阳、济南、温州、石家庄、福州、西安、遵义、郑州、重庆、银川、长春、长沙

  15. 正在招募
    Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
    分期
    I/II期
    开始
    2025-07
    发布
    登记号
    NCT07079475

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南京、天津、广州、成都、杭州、沈阳、济南、长沙

  16. 正在招募
    Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
    分期
    I/II期
    开始
    2025-04
    发布
    登记号
    NCT07087223

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院;另有 7 家列出的医院为研究中心北京、大连、天津、石家庄

  17. 正在招募
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    分期
    III期
    开始
    2025-12
    发布
    登记号
    NCT07182682

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 47 家列出的医院为研究中心上海、北京、南京、南宁、台州、合肥、哈尔滨、天津、太原、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、福州、西安、郑州、长春、长沙

  18. 正在招募
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    分期
    III期
    开始
    2025-12
    发布
    登记号
    NCT07185997

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、临沂、佛山、北京、南京、南宁、南昌、南通、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、新乡、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、潍坊、石家庄、福州、郑州、重庆、长沙、青岛

  19. 正在招募
    A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT06203210

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南昌、哈尔滨、天津、成都、杭州、武汉、沈阳、济南、烟台、襄阳、郑州、重庆、长沙

  20. 正在招募
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    分期
    III期
    开始
    2024-03
    发布
    登记号
    NCT06300177

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 63 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南宁、南昌、南通、厦门、合肥、哈尔滨、天津、太原、安阳、常州、广州、徐州、成都、新乡、无锡、昆明、杭州、桂林、武汉、沈阳、洛阳、济南、海口、温州、湛江、潍坊、石家庄、福州、西安、遵义、郑州、重庆、长春、长沙

  21. 正在招募
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT06345729

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、无锡、杭州、武汉、济南、温州、福州、苏州、西安、郑州、重庆、长沙

  22. 正在招募
    A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
    分期
    II期
    开始
    2023-06
    发布
    登记号
    NCT05913089

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、天津、太原、潍坊、福州

  23. 正在招募
    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
    分期
    III期
    开始
    2023-11
    发布
    登记号
    NCT05920356

    年龄 18 岁 至 100 岁(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、南通、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、成都、昆明、杭州、武汉、汕头、洛阳、济南、潍坊、石家庄、福州、蚌埠、襄阳、西安、郑州、重庆、长春、长沙

  24. 正在招募
    A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
    分期
    II期
    开始
    2023-12
    发布
    登记号
    NCT06010329

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、南京、南昌、哈尔滨、广州、成都、杭州、武汉、济南、郑州

  25. 正在招募
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    分期
    III期
    开始
    2022-03
    发布
    登记号
    NCT04928846

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南宁、南昌、南通、厦门、台州、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、昆明、杭州、武汉、汕头、沈阳、济南、湛江、石家庄、福州、西安、郑州、重庆、长春、长沙

  26. 正在招募
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
    分期
    II期
    开始
    2022-09
    发布
    登记号
    NCT05168566

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、北京、南京、哈尔滨、广州、成都、杭州、武汉、沈阳、蚌埠、郑州、长春、长沙

  27. 正在招募
    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
    分期
    I/II期
    开始
    2022-04
    发布
    登记号
    NCT05288205

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、临沂、北京、厦门、合肥、呼和浩特、哈尔滨、广州、武汉、沈阳、济南、深圳、福州、郑州、长沙

  28. 即将招募
    Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
    分期
    II期
    开始
    2025-03
    发布
    登记号
    NCT06885840

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心佛山、兰州、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、济南、西安、郑州、长春、长沙

  29. 即将招募
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    分期
    III期
    开始
    2023-05
    发布
    登记号
    NCT05767892

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、北京、南京、南昌、厦门、台州、合肥、呼和浩特、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、洛阳、济南、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科病理/检验科影像/核医学科放疗科

医院名称从作者地址自动识别,尚未人工核对。

牵头的论文80
  1. Superior Performance of Synchronized Percutaneous Microwave Ablation and Immediate Percutaneous Biopsy for Highly Suspected Malignant Pulmonary Ground-Glass Nodules.2026Journal of computer assisted tomography
  2. Global patterns and trends in mesothelioma incidence: A retrospective cross-sectional study.2026Lung cancer (Amsterdam, Netherlands)
  3. Multi-omics data-based modeling reveals tumorigenesis- and prognosis-associated genes with clinical potential in lung adenocarcinoma.2025BMC cancer免费全文
  4. Clinical and imaging features of co-existent pulmonary tuberculosis and lung cancer: a population-based matching study in China.2025BMC cancer免费全文
  5. Prognostic Value of Surgical Resection for Non-small-cell Lung Cancer Patients Comorbid With Minimal Pleural Effusion.2025Cancer control : journal of the Moffitt Cancer Center免费全文
  6. Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study.2025Cancer immunology, immunotherapy : CII免费全文
  7. Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non-Small Cell Lung Cancers.2025Cancer medicine免费全文
  8. Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study.2025Cancer science免费全文
  9. Effect of neoadjuvant targeted therapy on the tumor microenvironment in resectable lung adenocarcinoma.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  10. Two inflammation-related genes model could predict risk in prognosis of patients with lung adenocarcinoma.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico免费全文
  11. Impact of air pollution on the progress-free survival of non-small cell lung cancer patients with anti-PD-1/PD-L1 immunotherapy: A cohort study.2025Environmental pollution (Barking, Essex : 1987)
  12. Dose-dependent efficacy of CX1003 in NSCLC immunotherapy: High dose for T cell response, low dose for apoptosis.2025International immunopharmacology
  13. Combined detection of SHOX2 and PTGER4 methylation with serum marker CYFRA21-1 for improved diagnosis of malignant pleural mesothelioma.2025Journal of clinical pathology
  14. Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients.2025Journal of translational medicine免费全文
  15. Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1/PD-L1 blockades in NSCLC: a prospective exploratory study.2025Molecular biomedicine免费全文
  16. CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer patients.2025Signal transduction and targeted therapy免费全文
  17. A cohort study of circulating biomarkers to predict the efficacy and prognosis of immune combination therapy in non-small-cell lung cancer.2025The oncologist免费全文
  18. Peripheral Immune Cell Profiles as Predictive Biomarkers of Immune Checkpoint Inhibitor Efficacy in Elderly Patients With Advanced Non-Small Cell Lung Cancer.2025Thoracic cancer免费全文
  19. Predictive Value of the Estimated Dose of Radiation to Immune Cells Versus Conventional Parameters in Elderly Patients With Unresectable Stage III NSCLC: A Two-Center Real-World Study.2025Thoracic cancer免费全文
  20. Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.2025Thoracic cancer免费全文
  21. SARS-CoV-2 Infection Alters the Immune Microenvironment in Lung Cancer Patients Undergoing Immunotherapy and Affects Treatment Outcomes.2025Viruses免费全文
  22. The characteristics and prognoses of 72 postoperative synchronous multiple primary lung cancer patients.2025World journal of surgical oncology免费全文
  23. The Biological Role of Macrophage in Lung and Its Implications in Lung Cancer Immunotherapy.2024Advanced biology
  24. Identification of JUN gene and cellular microenvironment in response to PD-1 blockade treatment in lung cancer patients via single-cell RNA sequencing.2024Aging免费全文
  25. Artificial intelligence-driven computer aided diagnosis system provides similar diagnosis value compared with doctors' evaluation in lung cancer screening.2024BMC medical imaging免费全文
  26. Integration of clinical and blood parameters in risk prognostication for patients receiving immunochemotherapy for extensive stage small cell lung cancer: real-world data from two centers.2024BMC medicine免费全文
  27. Value of preoperative evaluation of FEV1 in patients with destroyed lung undergoing pneumonectomy - a 20-year real-world study.2024BMC pulmonary medicine免费全文
  28. A case of squamous cell carcinoma of the lung misdiagnosed as tuberculosis. Is HPV infected by oral sex the causative agent?2024BMC women's health免费全文
  29. Increased Incidence of Severe Adverse Events in Non-Small Cell Lung Cancer Patients with Previous Tuberculosis Episode Treated with PD-1 Inhibitors.2024Biomedical and environmental sciences : BES
  30. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.2024Cancer immunology, immunotherapy : CII免费全文
  31. The Ribonuclease ZC3H12A is required for self-inflicted DNA breaks after DNA damage in small cell lung cancer cells.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  32. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.2024Cellular signalling
  33. A deep learning model integrating multisequence MRI to predict EGFR mutation subtype in brain metastases from non-small cell lung cancer.2024European radiology experimental免费全文
  34. A case of neoadjuvant targeted therapy with pralsetinib for locally advanced lung adenocarcinoma with RET fusion mutation.2024Journal of cardiothoracic surgery免费全文
  35. The prognostic significance of lymph nodes in patients with pT1c33N0M0 non-small cell lung cancer: a retrospective study.2024PeerJ免费全文
  36. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Associated With Recurrence and Survival of Resectable Non-Small Cell Lung Cancer (NSCLC): A Retrospective Study.2024The Journal of surgical research
  37. Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature.2023Academic radiology
  38. Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer.2023BMC cancer免费全文
  39. Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer.2023BMC cancer免费全文
  40. Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer.2023BMC pulmonary medicine免费全文
  41. Chemotherapy for advanced pulmonary sarcomatoid carcinoma: a population-based propensity score matching study.2023BMC pulmonary medicine免费全文
  42. High accuracy epidermal growth factor receptor mutation prediction via histopathological deep learning.2023BMC pulmonary medicine免费全文
  43. Deep learning-based diagnosis of histopathological patterns for invasive non-mucinous lung adenocarcinoma using semantic segmentation.2023BMJ open免费全文
  44. Longitudinal detection of subcategorized CD44v6+ CTCs and circulating tumor endothelial cells (CTECs) enables novel clinical stratification and improves prognostic prediction of small cell lung cancer: A prospective, multi-center study.2023Cancer letters
  45. Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer.2023Cancer medicine免费全文
  46. CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy.2023European radiology experimental免费全文
  47. Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer.2023Frontiers in immunology免费全文
  48. Immunotherapy efficacy predictive tool for lung adenocarcinoma based on neural network.2023Frontiers in immunology免费全文
  49. PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer.2023Frontiers in immunology免费全文
  50. Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-κB activity via UHRF1/DNMT1 complex.2023International journal of biological sciences免费全文
  51. Two germline mutations can serve as genetic susceptibility screening makers for a lung adenocarcinoma family.2023Journal of cancer research and clinical oncology免费全文
  52. The artificial intelligence and machine learning in lung cancer immunotherapy.2023Journal of hematology & oncology免费全文
  53. Genetic profiling of circulating cell-free DNA from cerebrospinal fluid and paired plasma in ALK-positive lung cancer with brain metastases.2023Thoracic cancer免费全文
  54. ASO Author Reflections: A Simple Method to Predict Risk Factors of Complications After Pneumonectomy.2022Annals of surgical oncology
  55. A Multiple-Center Nomogram to Predict Pneumonectomy Complication Risk for Non-Small Cell Lung Cancer Patients.2022Annals of surgical oncology
  56. A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.2022BMC cancer免费全文
  57. Identification of serum MiRNAs as candidate biomarkers for non-small cell lung cancer diagnosis.2022BMC pulmonary medicine免费全文
  58. Expression and potential role of CCL4 in CD8+T cells in NSCLC.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  59. Circulating myeloid-derived suppressors cells correlate with clinicopathological characteristics and outcomes undergoing neoadjuvant chemoimmunotherapy in non-small cell lung cancer.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  60. CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer.2022Clinical and experimental immunology
  61. IncRNA Linc00511 Upregulation Elevates TGFBR1 and Participates in the Postoperative Distant Recurrence of Non-Small-Cell Lung Cancer by Targeting miR-98-5p.2022Critical reviews in eukaryotic gene expression
  62. Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.2022Diagnostic pathology免费全文
  63. Differentiating EGFR from ALK mutation status using radiomics signature based on MR sequences of brain metastasis.2022European journal of radiology
  64. CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer.2022Frontiers in immunology免费全文
  65. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8+ T cells in lung cancer.2022Immunotherapy
  66. Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer.2022Lung cancer (Amsterdam, Netherlands)
  67. Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration.2022Nature communications免费全文
  68. Long non-coding RNA BZRAP1-AS1 functions in malignancy and prognosis for non-small-cell lung cancer.2022PeerJ免费全文
  69. IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer.2021Biochemical and biophysical research communications
  70. Identification of a competing endogenous RNA axis "SVIL-AS1/miR-103a/ICE1" associated with chemoresistance in lung adenocarcinoma by comprehensive bioinformatics analysis.2021Cancer medicine免费全文
  71. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.2021Cancer medicine免费全文
  72. Engineering of hybrid anticancer drug-loaded polymeric nanoparticles delivery system for the treatment and care of lung cancer therapy.2021Drug delivery免费全文
  73. Associated factors of co-existent pulmonary tuberculosis and lung cancer: A case-control study.2021European journal of clinical investigation
  74. Hyaluronic Acid Correlates With Bone Metastasis and Predicts Poor Prognosis in Small-Cell Lung Cancer Patients.2021Frontiers in endocrinology免费全文
  75. Profiling of DNA damage and repair pathways in small cell lung cancer reveals a suppressive role in the immune landscape.2021Molecular cancer免费全文
  76. Role of aneuploid circulating tumor cells and CD31+ circulating tumor endothelial cells in predicting and monitoring anti-angiogenic therapy efficacy in advanced NSCLC.2021Molecular oncology免费全文
  77. Heterogeneity and prognosis of programmed cell death-ligand 1 expression in the circulating tumor cells of non-small cell lung cancer.2021Neoplasma
  78. Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma.2021Oncology reports免费全文
  79. A Modified Method to Isolate Circulating Tumor Cells and Identify by a Panel of Gene Mutations in Lung Cancer.2021Technology in cancer research & treatment免费全文
  80. ALK-rearranged squamous cell carcinoma of the lung.2021Thoracic cancer免费全文
中文论文(未计入)18
  1. [Analysis of the Correlation between Immune Cell Subsets in Bronchoalveolar Lavage Fluid and the Efficacy of First-line Use of Immunotherapy in Advanced Non-small Cell Lung Cancer: A Case-control Study].2024Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  2. [Clinicopathological Characteristics and Prognosis Analysis of 
39 Patients with Pulmonary Sarcomatoid Carcinoma].2024Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  3. [Clinical characteristics and prognostic factors of epidermal growth factor receptor-mutated non-small cell lung cancer transformed into small-cell lung cancer after treatment].2024Zhonghua yi xue za zhi
  4. [Aprospective study of detection and clinical significance of bone marrow tumor cells in small cell lung cancer].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  5. [Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview].2022Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  6. [Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review].2022Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  7. [Analysis of the Efficacy of Immunotherapy in Elderly Patients with Lung Cancer].2022Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  8. [Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer].2022Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  9. [Expression of CD44 in Tumor Tissue and Serum of Small Cell Lung Cancer and Its Clinical Prognostic Significance].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  10. [Analysis of the Efficacy of Immunotherapy on the Posterior Lines 
of Advanced EGFR Mutant Patients with Non-small cell Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  11. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with 
Chemotherapy in Resectable Non-small Cell Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  12. [Research Progress of Single Cell Sequencing in Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  13. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  14. [Application Progress of Immune Checkpoint Inhibitors 
in Oncogene-driven Advanced Non-small Cell Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  15. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  16. [Ongoing Evaluation of Immune-related Response Assessment in Brain Metastases].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  17. [Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  18. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)96
  1. Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC正在招募NCT06467617牵头方II期2024-08 启动
  2. The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)状态不明NCT03811054牵头方II期2018-12 启动
  3. Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)状态不明NCT01669707牵头方II期2011-04 启动
  4. A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.正在招募NCT06421298牵头方(推断)II期2024-05 启动
  5. A Study of DS-3939a in Participants With Solid Tumors正在招募NCT07739966研究中心I/II期2026-10 启动
  6. DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy正在招募NCT07472517研究中心III期2026-04 启动
  7. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer正在招募NCT07222566研究中心III期2026-01 启动
  8. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations正在招募NCT07195695研究中心III期2026-01 启动
  9. A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC正在招募NCT06962865研究中心II期2025-06 启动
  10. Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.即将招募NCT06885840研究中心II期2025-03 启动
  11. Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure正在招募NCT07087223研究中心I/II期2025-04 启动
  12. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)正在招募NCT06875310研究中心III期2025-04 启动
  13. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.正在招募NCT06758401研究中心III期2025-07 启动
  14. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations正在招募NCT07185997研究中心III期2025-12 启动
  15. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery正在招募NCT07182682研究中心III期2025-12 启动
  16. Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer正在招募NCT06712355研究中心III期2025-02 启动
  17. Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)正在招募NCT07079475研究中心I/II期2025-07 启动
  18. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)正在招募NCT06712316研究中心II/III期2025-01 启动
  19. A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)正在招募NCT06855771研究中心II期2025-09 启动
  20. Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)正在招募NCT06809764研究中心2025-02 启动
  21. A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy正在招募NCT07010263研究中心III期2025-06 启动
  22. A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer正在招募NCT06203210研究中心III期2024-05 启动
  23. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)正在招募NCT06345729研究中心III期2024-05 启动
  24. D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure正在招募NCT06300177研究中心III期2024-03 启动
  25. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)正在招募NCT05920356研究中心III期2023-11 启动
  26. A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC正在招募NCT06010329研究中心II期2023-12 启动
  27. YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations即将招募NCT05767892研究中心III期2023-05 启动
  28. A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer正在招募NCT05913089研究中心II期2023-06 启动
  29. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)正在招募NCT04928846研究中心III期2022-03 启动
  30. Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation正在招募NCT05288205研究中心I/II期2022-04 启动
  31. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer正在招募NCT05168566研究中心II期2022-09 启动
  32. A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors进行中,不再招募NCT07160335研究中心I期2025-09 启动
  33. A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer进行中,不再招募NCT06623136研究中心II期2025-04 启动
  34. Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy已终止NCT06924606研究中心II期2025-07 启动
  35. A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer进行中,不再招募NCT07005336研究中心II期2025-01 启动
  36. A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients状态不明NCT06469879研究中心III期2024-09 启动
  37. A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer进行中,不再招募NCT06012435研究中心III期2024-02 启动
  38. A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)进行中,不再招募NCT06593522研究中心II期2024-12 启动
  39. A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer进行中,不再招募NCT06984588研究中心II/III期2024-03 启动
  40. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients进行中,不再招募NCT05899608研究中心III期2023-10 启动
  41. A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery已完成NCT05872763研究中心2023-08 启动
  42. TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.状态不明NCT05718167研究中心III期2023-02 启动
  43. A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)进行中,不再招募NCT05722015研究中心III期2023-02 启动
  44. Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)进行中,不再招募NCT05609968研究中心III期2023-02 启动
  45. Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer进行中,不再招募NCT05740566研究中心III期2023-05 启动
  46. A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.状态不明NCT05598268研究中心I/II期2022-03 启动
  47. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)进行中,不再招募NCT05668988研究中心III期2022-12 启动
  48. A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer状态不明NCT05042375研究中心III期2022-09 启动
  49. A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer进行中,不再招募NCT05047250研究中心III期2022-06 启动
  50. Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer进行中,不再招募NCT05195632研究中心II期2022-06 启动
  51. A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)状态不明NCT04964479研究中心III期2021-08 启动
  52. A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer已终止NCT04746924研究中心III期2021-05 启动
  53. Lorlatinib Continuation Study进行中,不再招募NCT05144997研究中心IV期2021-12 启动
  54. Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)已终止NCT04738487研究中心III期2021-04 启动
  55. A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer已完成NCT04426825研究中心II期2020-09 启动
  56. Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer已完成NCT04665856研究中心III期2020-12 启动
  57. A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)已完成NCT04513925研究中心III期2020-08 启动
  58. Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC状态不明NCT04500704研究中心III期2020-10 启动
  59. A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China已完成NCT04830826研究中心2020-07 启动
  60. Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation状态不明NCT04500717研究中心III期2020-10 启动
  61. TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations已完成NCT04129502研究中心III期2020-01 启动
  62. A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)已完成NCT04194203研究中心III期2020-04 启动
  63. Cancer Genome Atlas of China:Lung Cancer状态不明NCT04266483研究中心2019-11 启动
  64. ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC状态不明NCT04143607研究中心III期2019-07 启动
  65. A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer状态不明NCT04439890研究中心III期2019-08 启动
  66. A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China已完成NCT03909971研究中心II期2019-04 启动
  67. A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer已完成NCT03596866研究中心III期2019-04 启动
  68. A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer状态不明NCT04641754研究中心II期2019-03 启动
  69. Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation已终止NCT04044170研究中心II期2019-07 启动
  70. A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer已完成NCT03594747研究中心III期2018-07 启动
  71. The Tracking Molecular Evolution for NSCLC (T-MENC) Study状态不明NCT03838588研究中心2018-11 启动
  72. A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer已终止NCT03516084研究中心III期2018-08 启动
  73. Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer已完成NCT03432598研究中心II期2017-08 启动
  74. Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)已完成NCT03358875研究中心III期2017-11 启动
  75. Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer状态不明NCT03502850研究中心I/II期2017-11 启动
  76. A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy已完成NCT02813785研究中心III期2016-07 启动
  77. A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients状态不明NCT04237805研究中心I/II期2016-11 启动
  78. eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients进行中,不再招募NCT02767804研究中心III期2016-06 启动
  79. A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)已完成NCT02838420研究中心III期2016-08 启动
  80. A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer已完成NCT02716116研究中心I/II期2016-06 启动
  81. Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)已完成NCT02388919研究中心II/III期2015-02 启动
  82. A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer已完成NCT02691299研究中心III期2015-12 启动
  83. Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early Stage Lung Cancer状态不明NCT02933294研究中心不分期2015-05 启动
  84. High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation状态不明NCT02404675研究中心IV期2015-04 启动
  85. Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma状态不明NCT02125240研究中心III期2014-09 启动
  86. A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer已完成NCT02590965研究中心II期2014-05 启动
  87. Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC已完成NCT01945021研究中心II期2013-09 启动
  88. Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)已完成NCT01982955研究中心I/II期2013-12 启动
  89. Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer已完成NCT01836679研究中心II期2013-04 启动
  90. A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients已完成NCT01639001研究中心III期2012-09 启动
  91. A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy已完成NCT01364012研究中心III期2011-05 启动
  92. Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer已完成NCT03117335研究中心III期2011-11 启动
  93. Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy已完成NCT02486354研究中心III期2010-03 启动
  94. BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)已完成NCT01121393研究中心III期2010-04 启动
  95. Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients已完成NCT01040780研究中心III期2009-02 启动
  96. Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population已终止NCT01015443研究中心III期2009-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

北京有 23 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

医院名称从作者地址自动识别,尚未人工核对。

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年没有牵头特发性肺纤维化的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 25 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

医院名称从作者地址自动识别,尚未人工核对。

中文论文(未计入)1
  1. [Protective effect of anti-idiopathic pulmonary fibrosis drug Pirfenidone and Sufenidone (SC1011) on pulmonary injury induced by tuberculosis in a mouse tuberculosis model].2023Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Safety and Efficacy of Nebulized 3D-cultured Human Placental Mesenchymal Stem Cell-derived Extracellular Vesicles (hPMSC-EVs) for Idiopathic Pulmonary Fibrosis即将招募NCT07515066牵头方(推断)I期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

首都医科大学附属北京胸科医院

Beijing Chest Hospital

北京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Beijing Thoracic Tumor and Tuberculosis Hospital; Central Tuberculosis Institute

提出更正下载数据